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ABSTRACT 
     The central nervous system operates through a tightly balanced relationship 
of excitatory and inhibitory synaptic transmission.  Neurosteroids, synthesized de 
novo from cholesterol in the human brain as well as converted from precursors 
circulating in the blood, are proven modulators of this synaptic activity.  
Pregnenolone sulfate, one of the most abundant endogenous neurosteroids, is a 
negative modulator of the GABA receptor and positive modulator of NMDA and 
AMPA receptors, increasing the frequency of excitatory transmission in the brain.  
Here, we show that low concentrations (50pM) of pregnenolone sulfate increase 
receptor trafficking in cultured rat hippocampal and cortical cells.  
Immunocytochemistry data shows that a ten-minute treatment with 50pM PS 
increases NR2B subunit protein.  Preliminary surface biotinylation results 
highlight a potential increase in NR1 subunit protein.  Since NMDA receptors play 
a pivotal role in learning and memory and have been implicated in 
neuropsychiatric disorder, an endogenous positive modulator of NMDA receptors 
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is likely to play a major pharmaceutical role in neurodegenerative and memory 
disorders. 
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ABBREVIATIONS 
 
3α-HSD 3α-hydroxysteroid reductase 
AMPA  2-amino- 3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propanoic acid 
BSA  Bovine serum albumin 
CNS  Central nervous system 
DHEA  Dehydroepiandrosterone 
DHEAS Dehydroepiandrosterone sulfate 
DMSO Dimethyl sulfoxide 
GABA  Gamma-aminobutyric acid 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP  Horseradish peroxidase 
ICC  Immunocytochemistry 
LTD   Long term depression 
LTP  Long term potentiation 
NMDA N-Methyl-D-aspartate 
PBS  Phosphate buffered saline 
PFA  Paraformaldehyde 
PS  Pregnenolone sulfate 
VCP  Valosin-containing protein  
VEH  Vehicle  
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INTRODUCTION 
 
     The central nervous system (CNS) is a precise and finely tuned machine that 
is programmed to respond to both excitatory and inhibitory modulation.  Every 
thought, action and process is rooted in the ability of the brain to recognize and 
differentiate between synaptic transmissions and translate them into chemical or 
mechanical responses.  
     Glutamate, an amino acid and extremely abundant neurotransmitter, is 
predominantly responsible for regulating excitatory synaptic transmission, while 
gamma-aminobutyric acid (GABA) is primarily responsible for mediating inhibitory 
synaptic transmission (Sieghart 1995; Dingledine et al., 1999). 
     The human brain operates through the interplay of these two processes; 
alteration within the finely tuned synaptic pathways of the CNS leads to an 
overall change in nervous system activity.  The ability to modulate either 
excitatory or inhibitory synaptic transmissions enables control of nervous system 
function.  This principle has been used successfully for years in the treatment of 
pain, stress, seizures and insomnia as well as within the field of anesthesiology 
(Bialer, 2012). 
     Research has allowed for the identification of several modulators of nervous 
system function, however, a family of molecules called “neurosteroids” has fallen 
under particular interest in recent years.  It has become well accepted that the 
human brain is a steroidogenic organ, synthesizing a number of these 
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neurosteroids de novo and recent research has been focused on identifying 
these molecules as well as understanding their structure and function (Reddy, 
2003). 
 
Neurosteroid Biosynthesis 
 
     The biosynthetic pathway of a neurosteroid begins with a cholesterol molecule 
and continues through a number of enzymatic steps mediated by two types of 
enzymes: cytochrome P450 and non-cytochrome P450 (Figure 1). 
Cytochrome P450 enzymes are heme-binding monooxygenases that are typically 
found as single genes that also have the ability to modulate a number of different 
enzymatic steps (Mellon, 2002).  On the other hand, the non-P450 enzymes are 
found as a multi-gene set that encodes for an array of proteins, each of which 
mediates a different reaction.   
     The biosynthesis of endogenous neurosteroids depends upon the collections 
of local steroidogenic enzymes on a tissue-specific basis (Do Rego et al., 2012).  
In the CNS, both glial and neuronal cells produce such enzymes and, 
furthermore, specific cellular regions within these cell-types express 
steroidogenic enzymes.  For example, P450scc, which mediates three separate 
steroidogenic reactions, is found in type I astrocytes and oligodendrocytes (two 
sub-types of glial cells) (Biagini et al., 2009), and a set of steroidogenic enzymes 
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capable of synthesizing PS de novo are expressed in hippocampal pyramidal 
neurons and a human brain glioma cell line (Kimoto 2001; Brown 2000) 
     To further the specificity of neurosteroidogenesis, it is worth noting that 
steroidogenic enzymes are not only cell-type and location specific, but are also 
specific to certain locations within neural cells (Compagnone, 2000).  
 
 
 
Figure 1: Pathway of Neurosteroid Biosynthesis.  Cholesterol undergoes several 
enzymatic steps involving cytochrome P450 and non-cytochrome P450 enzymes, 
resulting in the synthesis of neurosteroids or gonadal and developmental steroids 
(Figure taken from Shibuya et al., 2003). 
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     Neurosteroids are not only synthesized de novo from cholesterol in the brain; 
precursors circulating in the blood may also be converted to neuroactive steroids.  
For instance, in a series of enzymatic steps involving 5α-reductase and 3α-HSD 
(3α-hydroxysteroid reductase), progesterone is converted to allopregnanolone 
(Mellon, 2002: Do Rego et al., 2012). 
     The regional specificity of steroidogenic enzymes and the nature of precursor 
conversion make the function and location of endogenous neurosteroids very 
tissue and cell-specific.  It can therefore be reasoned that individual steroids 
have unique interactions with neural tissue and independent functions. 
 
GABAA Receptor 
 
     GABAA (γ-aminobutyric acid) receptors are a class of ubiquitously expressed 
ligand-gated ion channels found in the mammalian central nervous system.  They 
bind and are modulated by GABA as well as a collection of known 
pharmacological compounds. GABAA receptors are of particular pharmaceutical 
interest, as their modulation has been shown to have anxiolytic, analgesic, 
anticonvulsive, sedative, hypnotic and anesthetic properties (Belelli, 2005).   
     This class of receptors is hetero-oligomeric with each consisting of several 
membrane-spanning subunits serving to form a Cl- channel.  Receptors are 
composed of a number of α-subunits, β-subunits and γ-, δ-, ε-, π-, or θ- subunit 
types (Sieghart, 2002).  Subunit combinations within the GABAA receptor are 
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differentially expressed in different anatomical locations of the brain.  An example 
is seen with the α5 subunit, which can be found predominately in the 
hippocampus, an area of the brain that is associated with learning and memory 
(Wang, 2011).  Likewise, subunit composition has been shown to affect receptor 
function and ligand binding affinity, receptor channel kinetics, neuronal location of 
the receptor and pharmacological properties (Craig et al., 1998).  
     Modulation of GABAA receptors is responsible for a large amount of inhibitory 
transmission in the central nervous system.  When the receptor is activated, 
negatively charged chloride ions are free to enter the neuron, hyperpolarizing the 
membrane potential.  When the potential of the neuron falls below the threshold 
potential, it becomes increasingly more difficult to generate an action potential 
and thus excite nearby cells.  This mechanism is the driving principle behind 
neuropsychopharmacological drugs designed to have sedative, hypnotic, 
anticonvulsant or anesthetic properties.  Depressing the excitatory potential of 
the neuron prevents synaptic transmission and thus communication. 
 
NMDA Receptor 
 
     The N-Methyl-D-aspartate (NMDA) receptor is a heterotetrameric ionotropic 
glutamate receptor found in the mammalian brain.  It is composed of two 
NMDAR1 (NR1) subunits and two NMDAR2 and/or NMDAR3 subunits, with each 
subunit type containing two or more variants (Sanz-Clemente et al., 2012).   
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     Receptor activation requires co-binding of two ligands: glutamate and either d-
serine or glycine (Chen et al., 2011).  Once activated, the NMDA receptor is 
responsible for an inflow of Ca2+ and Na+ ions into and K+ ions out of the cell 
(Sharma et al., 2006) (Figure 2).  
 
Figure 2: NMDA receptor binding sites. The NMDA receptor is activated upon the co-
binding of two ligands: glutamate and either d-serine or glycine. Figure downloaded from 
“Wikipedia” at http://en.wikipedia.org/wiki/File:Activated_NMDAR.PNG 
 
     Calcium, being a well-known second messenger and tightly regulated cellular 
ion, is of particular interest in current research.  Excitotoxicity, or cell damage or 
death caused by an increased calcium level, can quickly result from an over-
activation of the NMDA receptor.  Modulation of the NMDA receptor has been 
shown to have implications in physiological processes such as learning and 
memory while also being involved with pathogenic conditions such as head 
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trauma, ischemic stroke, seizure activity and neurodegenerative disorders such 
as Huntington’s and Alzheimer’s diseases (Mony et al., 2009). 
     Much like GABA receptors, NMDA receptors exhibit functional variability 
based on the overall composition of subunits.  Subtypes show variation in 
expression as well as regional and synaptic location.  These receptors 
experience modulation through a number of molecular entities, including nitric 
oxide, zinc, polyamines, protons, arachidonate and neuroactive steroids 
(Dingledine 1999).  The potential for modulation gives the NMDA receptor 
pharmaceutical significance; agents designed to successfully target processes 
such as learning and memory or Alzheimer’s disease are of great scientific and 
medical interest. 
 
Neuronal Plasticity 
 
     The ability of the brain to gather information from new experiences or 
environments and synthesize memories is a critical function of the CNS.  In 
general, the process of forming a memory involves a physiological and/or 
chemical change in neuronal structure. 
     When considering neuronal plasticity specifically, the synapse is one of the 
most important anatomical feature of the neuron.  Standing as the 
communication interface between two neurons, features of the synapse control 
the frequency, strength and relative probability of neuronal transmission.  The 
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excitability of a neuron is the likelihood that the cell will receive and process an 
input and then generate an action potential that passes onto a subsequent 
neuron.  It is directly related to the type and distribution of ion channels within the 
synapse (Debanne et al., 2003). 
     One molecular method of learning is theorized to involve two processes: “long 
term potentiation”, or LTP, and “long term depression”, or LTD (Bliss,1993).  LTP 
occurs when there is a simultaneous stimulation of two adjacent neurons, 
resulting in a lasting enhancement in signal transmission.  Conversely, LTD 
involves a reduction in synaptic efficiency, normally lasting hours or more, 
following some type of modulatory stimulus.  The 2-amino- 3-(5-methyl-3-oxo-
1,2- oxazol-4-yl) propanoic acid (AMPA) receptor, like the NMDA receptor, is part 
of a class of ionotropic glutamate receptors that are responsible for mediating 
fast excitatory synaptic transmission in the CNS.  It is an ion channel that 
functions to, upon activation, allow for the passage of calcium and a number of 
other positive ions (Lee et al., 2003).  It has been shown that NMDA receptor 
activation leads to an increase in AMPA receptor trafficking and thus an increase 
in synaptic strength, one form of induced LTP (Bartlet, 2013).   
     Stimulation of NMDA receptors can be accompanied by an increase in 
synaptic surface AMPA receptors and by increased insertion of AMPA receptors 
at the surface of neuronal processes (Lu et al., 2001).  Activation of NMDA 
receptors leads specifically to an increase in AMPA insertion at the post-synaptic 
membrane (Molnar, 2011). 
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     NMDA receptor activation has also been proven to lead to long-term 
depression in neurons.  These receptors, through their ability to regulate calcium 
ion permeability, play a large role in the activation of downstream calcium-
dependent signal transduction pathways.  In this sense, NMDA receptors have 
an important position in the scheme of excitatory synaptic transmission (Lee et 
al., 2003).  While it is unclear how identical processes can cause opposite 
physiological effects, it has been postulated that total calcium exposure may be a 
cause.  For instance, LTP is triggered by a brief, potent increase of calcium ion 
concentration, while LTD results after a prolonged milder concentration of 
calcium ions is introduced.  It appears that the magnitude of calcium 
concentration as well as length of exposure plays a role in induction of LTP or 
LTD (Yang et al., 1998). 
 
Neurosteroid Modulation of Neuronal Receptors 
 
     Neurosteroids are endogenous molecular entities, synthesized de novo from 
cholesterol or converted from circulating steroid precursors.  They are proven 
modulators of neurotransmitter receptors, including GABAA, NMDA and AMPA 
receptors, among others.  Typically, the modulatory effect of a bound 
neurosteroid is fast, showing downstream actions within milliseconds to seconds 
(Wu et al., 1991), while traditional steroid interactions at the genome require 
minutes to hours (Rupprect et al., 2001).  
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     Modulatory effects of neurosteroids at similar sites of action may differ 
drastically.  For instance, pregnenolone sulfate (PS) and 
dehydroepiandrosterone sulfate (DHEAS) are both potent inhibitors of Cl- 
conductance at the GABAA receptor.  On the other hand, positive receptor 
modulation is exhibited by non-sulfated neurosteroids, allopregnanolone and 
pregnanolone, each of which potentiate GABAA receptors with high potency.  It is 
important to note that while a negatively charged group at the C-3 position 
converts many neurosteroids from positive to negative modulators, it is not 
completely necessary for inhibition.  Dehydroepiandrosterone (DHEA), the non-
sulfated derivative of DHEAS, for example, is also inhibitory at the GABAA 
receptor, although at a lower potency (Gibbs et al., 2006). 
     Pregnenolone sulfate, a negative modulator of the GABAA receptor, has also 
been shown to be a positive modulator of the NMDA receptor, further increasing 
the potential for excitatory synaptic transmission (Darnaudery et al., 2000).  This 
supports the hypothesis that neurosteroids, PS in particular, could be play a large 
role in long term potentiation, learning and memory or epilepsy (Wu et al., 1991; 
Collingridge, 1987). 
     Current studies point to synaptic glutamate receptors, namely NMDA 
receptors, and increased receptor expression playing a large role in enhanced 
memory formation and learning.  As LTP induction increases with an increased 
activation rate of NMDA and AMPA receptors, one theory says that receptor 
trafficking and activation are tightly connected to learning and memory 
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enhancement.  It has been shown that an increase in NR2B subunits within 
mouse hippocampal neurons resulted in faster completion times of working 
memory tasks such as the T-maze and a modified water maze (Stern, 2012). 
     Being that pregnenolone sulfate is a modulator of both NMDA and AMPA 
receptors, it has fallen under particular interest as a potential endogenous 
enhancer of learning and memory.  It is postulated that PS, through an increased 
activation rate of glutamate receptors and receptor trafficking, induces LTP in 
hippocampal neurons, thus strengthening synaptic connections and enhancing 
learning and memory processes (Lu et al., 2001). 
 
SPECIFIC AIMS 
 
     The study of neurosteroids is one that holds specific translational significance.  
As described, the proven ability to modulate excitatory synaptic transmission 
signifies a potential connection to processes such as learning and memory as 
well as Alzheimer’s disease, stroke recovery and a number of other CNS 
conditions.  A better understanding of the neural interactions, both chemical and 
physical, between neurosteroids and the brain requires sound foundational 
research.   
     Of the many endogenous neurosteroids that have been studied, we are 
interested in one in particular: pregnenolone sulfate.  This negatively charged, 
cholesterol-based molecule has been shown to increase excitatory synaptic 
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transmission in neurons and is therefore of specific interest to pharmacologists 
and neuroscience researchers.  Our interest lies in the desire to better 
understand the role of pregnenolone sulfate in the modulation of surface receptor 
trafficking in neurons and in the process of LTP. 
     It has been shown by members of our lab that low concentrations of PS 
(50pM) cause a quantifiable increase in intracellular calcium in neurons.  Thus, 
we hypothesize that 50pM PS increases the likelihood of receptor activation and 
neuronal excitability. To test this hypothesis, we performed immunocytochemistry 
(ICC) as well as surface biotinylation.  In quantifying both sets of experiments, we 
probed ICC samples for the NR2B receptor subunit and biotinylation experiments 
for NR1 and NR2B subunits as well as controls probing for valosin-containing 
protein (VCP) and Na+K+ATPase (negative and positive controls, respectively). 
 
MATERIALS AND METHODS 
 
Immunocytochemistry 
      
     Sprague Dawley rat E18 embryos were extracted and dissected and cultures 
were prepared from isolated hippocampal tissue using a procedure as in 
(Gravielle et al., 2005), with slight modification.  Cultures were allowed to mature 
for twenty-eight days on poly-L-lysinated (1mg/mL) glass coverslips in 24-well 
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plates in feeding media (96mL neurobasal media, 2mL B27, 1mL 
penicillin/streptomycin and 1mL Glutamax). 
     Cell cultures were treated with 50pM PS or 0.05% DMSO, prepared in 1X 
HEPES-buffered saline (in mM) NaCl 137, KCl 5, CaCl2 3, glucose 25, HEPES 
10, pH 7.3 at room temp. for 10 min.  The treatment solution was removed from 
the plates and we washed the cells once with 37°C 1X PBS.  Cultures were fixed 
using pre-warmed fresh 4% PFA/4% sucrose solution for two minutes at 37°C.  
To make 50mL of 4% paraformaldehyde (PFA), 42.5mL of deionized water was 
heated to 60°C and 2g of powdered PFA were added.  Drop-wise,10M NaOH 
was added until the solution cleared and then 5mL of 10X phosphate buffered 
saline was mixed into the solution (PBS; in 1L 10X PBS: 80g NaCl, 2g KCl, 14.4g 
Na2HPO4, 2.4g KH2PO4, enough H2O to fill to 1L).  The solution was cooled to 
37°C and the pH was adjusted to 7.3. 
     After incubation, the PFA was removed and replaced with -20°C MeOH.  The 
plates were then placed in the freezer for ten minutes.  After removing the 
methanol, the cells were permeabilized with 0.25% TritonX-100 in PBS for ten 
minutes at room temperature and the cultures were immediately blocked with 8% 
BSA/5% PBS for one hour at room temperature.  The blocking solution was 
removed and the cultures were incubated at room temperature with anti-NR2B 
antibody prepared in 5% donkey serum in PBS (1:200) for two hours. 
     After primary antibody incubation, the cell cultures were washed five times in 
1X PBS for five minutes each followed by incubation with the secondary antibody 
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(1:1000), goat anti-rabbit HRP, for two hours at room temperature.  Cells were 
again washed five times for five minutes each with 1X PBS and coverslips were 
mounted onto glass slides using ProLong Antifade mounting media.  After thirty 
minutes, once the mounting media had set, the coverslips were sealed using a 
thin film of clear nail polish. 
     Mounted coverslips were imaged under fluorescence at BioSquare imaging 
facility using fluorescence wide-field microscopy and a lab member, to eliminate 
bias during analysis, coded the images.  Each obtained image was analyzed 
using the FIJI software program and a lab-derived algorithm.  Within each region 
of interest, representative background pixels were selected and their intensity 
values were averaged. These values were multiplied by 1.5 in order to eliminate 
background and isolate puncta for counting.  Once the image backgrounds were 
subtracted, FIJI was used to analyze the selected regions of interest and puncta 
number, size and intensity values were recorded.  These data were compared 
between proximal and distal dendrites with distal dendrites being those 100um 
from the soma or after first branch point for large neurons. 
 
Biotinylation and Immmunoprecipitation 
 
     Biotinylation, followed by immunoprecipitation to examine surface receptors,  
was carried out using cultures obtained as described previously.  Cultures were 
allowed to mature for twenty-eight days on poly-L-lysinated (1mg/mL) glass 
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coverslips in 24-well plates in feeding media (96mL neurobasal media, 2mL B27, 
1mL penicillin/streptomycin and 1mL Glutamax).  
     Prior to treatment and biotinylation, 20mL solutions of 50pM PS and 0.05% 
DMSO in HEPES (1L 5X HEPES: 40g NaCl, 1.85g KCl, 1.90g MgCl2, 1.90g 
EGTA, 22.5g Glucose, 11.9g HEPES and enough H2O to fill to 1L) were 
prepared.  Also prepared was a 50mL bicarbonate buffer solution (BN: 2.5mL 
10X bicarbonate buffer [GE Healthcare product #1061925], 1.5mL 5M NaCl and 
H2O to volume), biotinylation solutions (per plate: 4mL BN + 20uL biotinylation 
reagent + 2uL PS or 2uL DMSO solution) and a 50mL lysis buffer solution 
(44.5mL tris-buffered saline pH 8.0 (TBS), 5mL glycerol, 0.5mL NP40 [IGEPAL 
CA-630] and one Complete protease inhibitor tablet [Roche 11-697-498001]) 
     Each 10cm plate was washed twice with room temperature 1X PBS and one 
time with room temperature 1X HEPES.  The plates were then treated with 4mL 
of either PS or DMSO (Vehicle, VEH) and placed in an incubator at 37°C for ten 
minutes.  The treatment solutions were removed and the plates were rinsed one 
time with bicarbonate buffer mixture (2000:1 BN:PS or 2000:1 BN:DMSO, 
respectively).  4mL of biontinylation solution was added to each plate, and left to 
incubate at room temperature for ten minutes.  After incubation, 75uL of 1M Tris 
(pH 8.0) was added and the plates were inclubated for another ten minutes at 
room temperature to quench the biotinylation reaction.  Once the reaction had 
been quenched, each plate was rinsed twice with ice-cold PBS, 500uL lysis 
buffer was added and the plates were transferred to an ice bucket. 
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     Using a cell scraper, the cells were scraped from the plates and similar 
treatment conditions were pooled into the same eppendorf tubes and labeled 
accordingly.  For ten minutes, the lysis buffer/cell solutions were mixed by 
inversion in a cold room (4°C) and then centrifuged for ten more minutes at 
13,000rpm.  The supernatant was pipetted into another eppendorf tube, labeled 
accordingly and the pellet was discarded. 
     In order to determine protein concentrations of our sample solutions, a 
Bradford Protein Assay was run.  Mixing 50uL of a 2mg/mL Bovine Serum 
Albumin (BSA) stock with 50uL deionized water, a 1mg/mL BSA solution was 
made.  If frozen, sample solutions were removed from the freezer and allowed to 
thaw before Bradford Assay standards were prepared in duplicate (Figure 2).  It 
is important to note that the lysis buffer that was used earlier in the biotinylation 
procedure must be used at this point during the Bradford Protein Assay.  Several 
freeze-thaw processes are discouraged. 
 
Table 1: Bradford Protein Assay standard and sample preparation protocol.  We 
used these chemical quantities to prepare solutions in preparation for the Bradford 
Protein Assay. 
 
Standard H2O (uL) Lysis Buffer (uL) BSA (µL) 
A (1 µg) 795 4 1 
B (2 µg) 794 4 2 
C (5 µg) 792 4 4 
D (10 µg) 788 4 8 
E (20 µg) 780 4 16 
Blank 796 4 0 
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     For the unknown samples, 796uL of water was added to 4uL of sample 
solution.  Once standards and samples were prepared, 200uL of Bio-Rad Protein 
Assay dye (Bio-Rad product # 500-0006) was added and the samples were 
vortexed.  The samples were then allowed to incubate at room temperature for 
twenty minutes.  After the incubation period, the solutions were vortexed and 
200uL of each was loaded into the wells of a clear plastic microplate (96-well 
microplate: Corning costar EIA/RIA plate product # 9017).  The solutions were 
measured using a spectrophotometer and the absorbance of the standards 
versus protein concentration was plotted and extrapolated to determine 
concentration of protein in the unknown samples. 
     Using the extrapolated data, 1000ug of protein was added to a tube from each 
sample and the volume of each was adjusted to 1mL using lysis buffer before 
adding 50uL of NeutrAvidin slurry to each tube.  These tubes were left to 
incubate rocking overnight at 4°C.  The next day, the samples were centrifuged 
at 13,000rpm for ten minutes and the supernatant was discarded.  Each pellet 
was resuspended in 1mL of lysis buffer and centrifuged three times followed by 
resuspension in 1mL of H2O. 
     Samples were centrifuged and the water was removed.  A mixture of 1mL 
sample buffer and 50uL β-mercaptoethanol was prepared and 50uL was added 
to each pellet.  Likewise, total protein standards of 3ug, 6ug, 12ug and 18ug 
were prepared.  Samples and standards were run on a Western Blot in duplicate, 
probed with anti-NR1 and anti-Na+K+ATPase, developed and quantified.  After 
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quantification, each membrane was stripped and probed with anti-VCP and anti-
NR2B antibodies and developed. 
     Each of the films was scanned and quantified for each antibody and each 
condition, PS versus VEH.  Once band intensity had been measured, a chart 
based on the loaded total protein standards was created.  Ideally, this chart 
would be as close to linear as possible, but in an effort to standardize 
quantification, a best-fit line was added to the data.  After identifying the best-fit 
linear equation, PS and VEH surface biotinylation sample band intensities were 
added and extrapolated to find their apparent protein concentration on the curve.  
Upon comparing PS and VEH extrapolated values, it was possible to note either 
an increase or decrease after drug treatment. 
 
RESULTS 
 
Immunocytochemistry  
      
     Our intention was to determine whether 50pM PS (prepared in HEPES) 
changes neuronal excitability, observable as redistribution of receptors and 
synaptic proteins involved in synaptic transmission.  In order to determine if 
treatment with 50 pM pregnenolone sulfate would alter the localization of NR2B 
we performined immunocytochemistry experiments probing specifically for NR2B, 
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a synaptic protein marker. This protein is essential for neuronal transmission and 
has been shown to redistribute with alterations in neuronal excitability.   
     For quantification purposes, our analysis focused on comparing diffuse versus 
punctate NR2B distribution.  Diffuse distribution manifests as a smother, more 
consistent staining while punctate distribution consists of smaller, brighter, more 
definitive points of NR2B staining.  We are specifically interested in NR2B puncta 
in this study, because current theories highlight the increased presence of 
synaptic and dendritic puncta during LTP (Kopec et al., 2006).  Through the 
treatment of rat hippocampal cells with pregnenolone sulfate, our intention was to 
Examine alterations in the number of NR2B puncta as an indication of PS-
induced alterations in neuronal activation/excitability.     
     Ten-minute treatments of hippocampal cells with 50pM pregnenolone sulfate 
and VEH and subsequent ICC staining allowed us to observe neurosteroid-
influenced effects on puncta quantity and location (Figure 3).  We analyzed over 
36 different image fields and over 180 specific regions of interest taken from rat 
hippocampal culturing sessions.  Each of the images was analyzed using the FIJI 
software program, providing us with puncta counts and intensity and size values 
for each selected region of interest. 
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Figure 3: 10min 50pM PS increases proximal NR2B puncta.  Representative images 
showing that the number of NR2B puncta on proximal dendrites increases after a 10min 
treatment with 50pM PS (Right) in dissociated hippocampal neuronal cultures (28DIV), 
compared to VEH (Left) (0.05% DMSO) No significant change was observed for distal 
dendrites undergoing the same treatment regimen. Images were taken with a 
fluorescence wide-field microscope at 100X (Scale bar = 10µm). Experiment performed 
collaboratively with and image prepared by Kavitha Sugunan.   
 
 
 
     Once image analysis was completed and the images were decoded, we 
pooled the data for treated versus untreated images as well as proximal versus 
distal regions of interest and ran a t-test on the results.  It was determined that 
there was a significant increase in the number of puncta located proximally when 
the neurons were treated with 50pM pregnenolone sulfate (p = 0.0044).  
Conversely, we were able to observe no significant change in number of puncta 
located on distal dendrites when the same treatment was applied.     
     Our analysis also included a comparison of the change in NR2B puncta 
density between proximal and distal dendrites after ten-minute treatments with 
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50pM pregnenolone sulfate.  Using the same method of puncta analysis, we 
were able to pool data and perform statistical t-tests to quantify the results.  
Figure 3 and figure 4 display fluorescence wide-field microscopy images of 
proximal and distal hippocampal neurons treated with PS for ten minutes, 
respectively.  It is possible to observe a more concentrated staining and brighter 
fluorescence in the dendritic regions closer to the soma, highlighting the 
increased expression of NR2B subunit protein proximally in figure 3.  On the 
other hand, figure 4 displays distal dendrites, which exhibit a uniform density of 
staining and lack of change in puncta expression. 
 
 
Figure 4: 10min 50pM PS does not affect distal NR2B puncta.  Representative 
images showing that the number of NR2B puncta on distal dendrites does not increase 
after a 10min treatment with 50pM PS (Right) in dissociated hippocampal neuronal 
cultures (28DIV), compared to VEH (Left) (0.05% DMSO) Images were taken with a 
fluorescence wide-field microscope at 100X (Scale bar = 10µm) Experiment performed 
collaboratively with Kavitha Sugunan.   
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     Upon performing statistical analysis, it was discovered that a ten-minute 
treatment with pregnenolone sulfate caused a statistically significant increase in 
puncta per unit length (20µM) proximally on the dendrite when compared to 
treatment with 0.05% DMSO (VEH) (t-test, p = 0.0044; 36 fields, 180 ROIs, 2 
rats).  In contrast, we found that there was no statistical change in puncta per 
20µM when distal dendritic fields undergoing the same treatment were analyzed 
(t-test, p = 0.4564; 36 fields, 180 ROIs, 2 rats) (Figure 5). 
 
Figure 5: Effect of a 10-min, 50pM PS treatment on NR2B in dissociated 
hippocampal neuronal cultures (28DIV) per 20µM. The number of puncta per 20µm 
proximal dendritic length increases after a 10min treatment with 50pM PS, compared to 
VEH (0.05% DMSO) (t-test, p = 0.0044; 36 fields, 180 ROIs, 2 rats). No significant 
change was observed for distal dendrites undergoing the same treatment regimen (t-
test, p = 0.4564; 36 fields, 180 ROIs, 2 rats). Experiment performed collaboratively with  
Kavitha Sugunan. 
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     It was initially theorized that average NR2B puncta size would be expected to 
increase upon treatment with PS.  However, we determined that for both 
proximal and distal dendritic regions, puncta size does not change significantly 
after a ten-minute treatment with 50pM pregnenolone sulfate, compared to VEH 
(t-test, p = 0.0955 and 0.7320, respectively, 36 fields, 180 ROIs, 2 rats) (Figure 
6).  It is worth noting that, while not significant, a mild increase in average NR2B 
puncta size in PS treated neurons proximally was observed, while, distally, little 
difference was seen. 
 
 
Figure 6: Effect of a 10-min, 50pM PS treatment on NR2B puncta size in 
dissociated hippocampal neuronal cultures (28DIV). The NR2B puncta size does not 
change significantly after a 10min treatment with 50pM PS, compared to VEH (0.05% 
DMSO) , for both proximal and distal dendrites (t-test, p = 0.0955 and  0.7320, 
respectively, 36 fields, 180 ROIs, 2 rats). Experiment performed collaboratively with 
Kavitha Sugunan. 
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     To further study the effects of pregnenolone sulfate on NR2B puncta, we 
compiled the image data to create a frequency distribution of NR2B puncta in 
proximal versus distal dendrites.  We found that the cumulative frequency 
distribution of puncta located in proximal dendrites shows that a lower frequency 
of puncta ranging in size from 10 to 60 pixel2 results from a ten-minute 50pM PS 
treatment, compared to VEH.  Distally, however, we observed no noticeable 
difference in frequency distribution of NR2B puncta sizes between ten-minute PS 
and VEH treatments (Figure 7).   
     These results may agree with the slight difference in average puncta size 
exhibited in figure 6, however, they do not allow us to make any sort of 
conclusion with regards to the significance of the data.  Also of importance is the 
fact that figure 7 highlights a decrease in the number of smaller puncta between 
10 and 60 pixel2 and does not necessarily tell us that the average size of puncta 
is increasing with a ten-minute treatment of pregnenolone sulfate, proximally.  It 
is not possible to make a conclusion in either direction and, therefore, it is 
necessary to study this association further. 
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Figure 7: Effect of a 10-min, 50pM PS treatment on frequency of NR2B puncta size 
in dissociated hippocampal neuronal cultures (28DIV). The cumulative frequency 
distribution of NR2B puncta located in proximal dendrites show that a 10-min 50pM PS 
treatment results in a lower frequency of puncta ranging in size from 10 to 60 pixel2, 
compared to VEH (0.05% DMSO) (36 fields, 180 ROIs, 2 rats).  In contrast, in the distal 
dendrites, no difference in frequency distribution of NR2B puncta size is observed 
between VEH and PS treatments. Experiment performed collaboratively with Kavitha 
Sugunan. 
 
 
Biotinylation and Immunoprecipitation 
 
     Our aim in performing biotinylation and Immunoprecipitation experiments is to 
ultimately identify if ten-minute treatment with 50pM pregnenolone sulfate causes 
a change in surface receptor density.  We theorize that PS, a positive modulator 
of excitatory synaptic transmission, will increase the concentration of biotinylated 
surface NR1 and NR2B receptor subunits.  Ideally, this result would indicate an 
increase in synaptic excitability as caused by PS treatment. 
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     Initial results are promising; they do, however, require further optimization and 
fine-tuning before any conclusions can be drawn.  Figure 8 shows a preliminary 
Western Blot probe for the NR1 subunit of the NMDA receptor.  As the NR1 
subunit is the only required NMDA receptor subunit, any increase in receptor 
protein would signify an increase in NMDA receptor concentration. 
     Seen below and on the right, the PS treated cortical culture appears to show 
an increase in total surface biotinylated NR1 protein (Figure 8).  The intensity of 
the left-most band on the upper row seems to be deeper in intensity compared to 
its counterpart on the left.  This result agrees with our initial hypothesis that 
pregnenolone sulfate, in 50pM concentrations, will increase the excitability of 
neurons treated for ten minutes. 
 
 
 
 
      
Figure 8: Effect of a 10-min, 50pM treatment on biotinylated surface NR1 protein.  
Western blots probing for surface NR1 (left lane) and 18ug, 12ug, 6ug and 3ug total 
protein samples (lanes 2 through 4, respectively, left to right).  PS treated cells (right) 
show an apparent increase in biotinylated surface protein as compared to VEH (0.05% 
DMSO, left).  
 
 
     After probing for NR1, we probed the same membrane for NR2B, a second 
subunit of the surface NMDA receptor.  Figure 9 shows results after a ten-minute 
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treatment with either PS or VEH (0.05% DMSO, left and right respectively) and 
overnight probe with anti-NR2B antibody.  There appears to be a slight decrease 
in biotinylated surface receptor protein concentration after treatment with 
pregnenolone sulfate, contrary to what we theorized.  NR2B, as compared to 
NR1, however, is not a required subunit of the NMDA receptor; a decrease in 
NR2B does not necessarily indicate a decrease in surface NMDA receptors.  It is 
possible that expression of a single subunit may decrease while the expression 
of a second subunit is increased. 
     It is important to note, however, that probing for the intracellular negative 
control, VCP, gave us a signal on our Western Blot membranes.  This result 
could have been caused by any number of factors, ranging from cellular 
physiology and morphology to unhealthy cell cultures.  On the other hand, this 
data is promising, as it alludes to a noticeable effect that can be further studied 
after protocol optimization and procedural alterations. 
 
 
Figure 9: Effect of a 10-min, 50pM treatment on biotinylated surface NR2B protein. 
Western blots probing for surface NR2B (right lane) and 18ug, 12ug, 6ug and 3ug total 
protein samples (lanes 2 through 4, respectively, right to left).  PS treated cells (right) 
show an apparent decrease in biotinylated surface protein as compared to VEH (0.05% 
DMSO, left). 
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DISCUSSION 
 
Immunocytochemistry 
 
     The human central nervous system is the target for modulation by numerous 
chemical entities, both endogenous and synthetic.  Neurosteroids, derived from 
cholesterol and synthesized de novo in the central or peripheral nervous systems 
or converted from chemical precursors, have been shown to bind to neuronal 
membrane-bound receptors and alter the activity of neurons either in an 
excitatory or inhibitory fashion (Paul, 1992). 
     These steroids are of particular interest to researchers and physicians, as 
neurosteroids have been implicated as potential therapeutic agents for conditions 
such as depression, anxiety and psychosis (Rupprecht et al., 2001) as well as 
seizures, insomnia, sedation, learning, memory and pain (Gibbs et al., 2006).  
With the potential to also utilize these steroids to modulate excitatory or inhibitory 
transmission in patients with further conditions such as Alzheimer’s or 
Huntington’s disease, the future for the field of neurosteroids is not only exciting 
but is also very bright. 
     As with any pharmaceutical agent, it is necessary to perform foundational 
research; our aim in performing these studies is to better understand the 
interactions of neurosteroids, namely pregnenolone sulfate, in the nervous 
system and to observe their role in surface receptor trafficking in neurons.  Better 
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understanding these interactions opens the door to countless potential further 
studies. 
     Immunocytochemistry allowed us to quantify the potential change in neuronal 
excitability and the redistribution of surface receptor proteins upon stimulation 
with a low concentration of pregnenolone sulfate.  One of our initial results 
showed that ten-minute treatment with PS (compared to ten-minute treatment 
with VEH) caused an increase in NR2B puncta proximally on the dendrite.  On 
the other hand, we did not report a similar finding when observing distal dendrites 
undergoing the same treatment. 
     An increase in NR2B puncta post-treatment would presumably signify an 
increase in excitability of the neuron.  As a known subunit of the NMDA receptor, 
NR2B proteins are key members of the glutamate-gated ion channels involved in 
excitatory synaptic transmission, synaptic plasticity, and excitotoxicity (Petrovic et 
al., 2009).  Calcium, a tightly regulated ion and important second messenger in 
cellular processes, gains entry into the neuron upon NMDA activation.  
Therefore, a higher concentration of NR2B subunits signifies a potential increase 
in surface NMDA receptors, which leads to an increased potential for calcium 
inflow and cellular activation. 
    Figure 5 describes an observed and statistically significant increase in 
proximal NR2B subunits per unit length (20µm) after ten-minute treatment with 
50pM pregnenolone sulfate, while distal dendritic regions show no observable 
increase versus VEH treatment.  
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     As is shown in Figure 3, an increase in NR2B subunit concentration alludes 
to, but does not necessarily guarantee, an increase in NMDA receptor 
concentration.  Of all possible NMDA receptor subunits, the NR1 subunit is the 
only subunit protein that is expressed in every receptor.  On the other hand, the 
NR2B subunit is considered to be variable and is not always expressed in NMDA 
receptors.  That being said, an increase N-methyl-d-aspartate receptor subtype 
2B (NR2B) has been implicated specifically in the enhancement of learning and 
memory in mice (Jang et al., 2004). 
     Studies have thus proven that an increase in total NMDA receptor 
concentration is not required for an enhancement of cognitive ability; NR2B alone 
is indicated as necessary.  Our results, then, shed light on the potential for 
pregnenolone sulfate to be used as cognitive enhancer.  Further study must be 
done to conclusively implicate this neurosteroid, however, with 36 fields 
captured, 180 regions of interest selected and two separate organisms studied, 
our results are a sound foundation on which to base for future research. 
     As shown in figure 6, we were unable to observe an increased average 
puncta size after ten-minute treatment with 50pM pregnenolone sulfate.  
Interestingly, though, there was a decrease in the frequency of puncta size 10 to 
60 pixel2 located on proximal dendrites after treatment.  On distal dendrites, 
treatment with PS versus VEH showed no change in the frequency distribution 
(Figure 7).  It is possible to note a slight, yet not-statistically significant, increase 
in puncta size on PS treated proximal dendrites.  These charts seem to be at 
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odds, however, it is important to remember that noting a decrease in puncta 10 to 
60 pixel2 is not the same as claiming that PS causes an increase in average 
puncta size.  Both observations must be made independently and should not be 
confused. 
      Overall, our immunocytochemistry results highlight a significant effect of PS 
on NR2B puncta.  We have shown that there is a quantifiable increase in both 
the number and location of receptor subunits in ten-minute treatment conditions.  
At this point in our study, we have obtained results that demand further research 
and experimentation to explain. 
 
Biotinylation and Immunocytochemistry 
 
     Preliminary data for our biotinylation experiments play a very interesting role 
in directing future studies.  We only just began running these experiments but are 
already showing the potential for identifying and supporting neurosteroid 
modulatory effects. 
     Currently, we are interested in observing the effects of a ten-minute treatment 
of 50pM pregnenolone sulfate on cultured rat cortical cells.  As neurosteroids 
have been implicated in surface receptor trafficking, we biotinylate surface 
proteins and subsequently probe for NR1 and NR2B subunits in an attempt to 
show an increase in receptor concentration upon stimulation with pregnenolone 
sulfate. 
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     Our initial probe for NR1, as seen in figure 8, shows robust bands for both PS 
and VEH samples, with the pregnenolone sulfate treated sample showing a 
seemingly darker band.  On the other hand, the NR2B Western Blot seen in 
figure 9 exhibits a VEH sample band that is darker in appearance, compared to 
that of the PS sample.  Again, these data should be observed with the 
understanding that the negative control showed a small protein band for valosin-
containing protein and that there will be several aspects of the experimental 
protocol that will be evaluated and altered in the future. 
     Several positive findings can be drawn from these biotinylation data.  For 
each experiment, we loaded 1000ug of biotinylated sample protein; this amount 
of protein provided a deep signal, proving that both NR1 and NR2B subunit 
proteins are expressed in sufficient concentrations in rat cortical cells that are 
only eight days old in culture.  Likewise, we were able to identify that 
concentrations of both cell surface NMDA receptor subunits are quantifiable by 
surface biotinylation and immunoprecipitation protocols.  We also had the 
opportunity to identify and optimize antibody type, dilution and incubation time for 
NR1, NR2B, VCP and Na+K+ATPase primary and secondary antibodies.  
     Specifically, there are several aspects of the protocol that we have identified 
as requiring modification.  As can be seen in both figure 8 and figure 9, the 
sample bands show significant streaking.  Band streaking can be caused by 
several different experimental factors but we have determined that our initial 
sample buffer was utilized with an incorrect dilution.   
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     Approaching these experiments with a forward thinking mind has given us the 
opportunity add a second layer of control, separate from probing for positive and 
negative control proteins.  For future biotinylation experiments, we have decided 
that it will be necessary to show that total protein sample loadings have similar 
protein concentrations.  While an automated Excel spreadsheet calculated 
sample volumes to be added, based on determined protein concentration (from 
running a Bradford Protein Assay), there is no way to prove that total protein 
standards contain equal protein concentrations.  To remedy this gap, we will load 
a single lane on the PS nitrocellulose gel with a total protein standard from VEH 
that is equal in value to one of the PS standards.  For instance, if our total protein 
standards consist of 18ug, 12ug, 6ug and 3ug, on the PS gel, we will load each 
of the four standards prepared from PS total protein sample as well as a 12ug 
standard prepared from the VEH total protein sample.  In doing so, we will be 
able to compare band intensity after developing.  Ideally, the 12ug PS standard 
will be identical to the 12ug VEH standard and we will be able to negate any 
doubt as to the presence of variables introduced by analyzing separate 
membranes transferred from separate gels, etc. 
     One further step that we will take in order to limit potential experiment 
variability and inconsistency will be loading five total protein standards, as 
opposed to our previous four, and two different biotinylated protein 
concentrations.  In doing so, we will increase the accuracy of our standard curve 
and thus our best-fit line, as well as giving ourselves two potential surface protein 
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values to compare.  One of the potential problems in quantifying a biotinylation 
experiment results when the surface protein band is thicker than the highest 
concentration total protein standard.  While the best-fit line theoretically extends 
into infinity, extrapolating to a value higher than your highest standard casts 
potential doubt on resulting conclusions.  Our intention is to identify any and all 
potential questions that could result upon data presentation and add additional 
controls to be used to verify and support our data. 
     Taking preliminary data and changes to the protocol into account, there is 
much promise for future biotinylation and immunoprecipitation experiments.  Our 
hypothesis will remain the same: treatment with 50pM pregnenolone sulfate, 
through modulation of surface receptor trafficking, will result in an increased 
concentration of NR1 and NR2B NMDA receptor subunits.  Newly implemented 
controls will serve to support our experimental results and prevent any potential 
doubt. 
     Baseline experimental data has supported the claim that neurosteroids, 
pregnenolone sulfate in particular, modulate surface receptor trafficking in 
neurons.  We have shown, through immunocytochemistry, that ten-minute 
treatment with 50pM pregnenolone sulfate increases the total amount of 
expressed surface NR2B NMDA receptor subunits as well as total subunits per 
20µm on distal dendrites.  Likewise, our data show that ten minute PS treatments 
decrease the frequency of distally expressed puncta between the sizes of 10 and 
60 pixel2.  We have also shown that preliminary cell surface biotinylation and 
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immunoprecipitation experiments indicate that cortical cultures that have matured 
for eight days in feeding media express NR1 and NR2B subunits in concentrated 
amounts that can be biotinylated and imaged through Western Blot 
experimentation.  Initial immunoprecipitation shows that PS treated cells may 
potentially express NR1 at a higher rate as compared to cells comparably treated 
with VEH.  Further study will elucidate any change that PS has on NR1 and/or 
NR2B surface receptor concentration. 
     Neurosteroids have been identified as potent modulators of neural activity.  
Studies have shown them to be both inhibitory and potentiating modulators of 
synaptic transmission and neuronal excitability.  They are of particular interest to 
researchers and physicians alike, as synaptic transmission plays a major role in 
several conditions such as depression, learning and memory, Alzheimer’s and 
Huntington’s disease, stroke recovery, seizures, sedation and pain.  The 
potential for using these endogenous steroids as pharmaceutical agents is still 
being uncovered and developed.  Pregnenolone sulfate continues to be the main 
focus of our experiments and future studies will allow us to shed even more light 
on its modulatory affects and potential pharmacological use. 
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